Single Peptides

HGH 191AA (10IU Vial) Dosage Protocol

HGH 191AA (10IU Vial) Dosage Protocol

Quickstart Highlights

HGH 191AA is recombinant human growth hormone (somatropin) identical to endogenous GH, studied extensively for its effects on body composition, metabolism, and tissue repair[1][7]. Clinical protocols typically employ subcutaneous administration once daily to mimic physiological GH secretion patterns[2][3]. This educational protocol presents a gradual titration approach using practical dilution for precise insulin-syringe measurements.

  • Reconstitute: Add 3.0 mL bacteriostatic water → ~1.11 mg/mL concentration (~1111 mcg/mL).
  • Typical daily range: 150–500 mcg (conservative replacement protocols)[1] to 1000–2000 mcg (advanced metabolic studies)[4].
  • Easy measuring: At 1.11 mg/mL, 1 unit = 0.01 mL ≈ 11.1 mcg on a U-100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

 Dosing & Reconstitution Guide

Standard / Gradual Titration (3 mL = ~1.11 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Week 1 200 mcg 18 units (0.18 mL)
Week 2 300 mcg 27 units (0.27 mL)
Week 3 400 mcg 36 units (0.36 mL)
Week 4 500 mcg 45 units (0.45 mL)
Week 5 600 mcg 54 units (0.54 mL)
Week 6 700 mcg 63 units (0.63 mL)
Week 7 800 mcg 72 units (0.72 mL)
Week 8 900 mcg 81 units (0.81 mL)

Frequency: Inject once daily subcutaneously, preferably at bedtime to mimic physiological GH secretion[2]. Rotate injection sites to prevent lipoatrophy[3]. This 8-week protocol represents a conservative approach with gradual dose escalation by approximately 100 mcg per week.

Extended 12-Week Protocol (Optional)

Week Daily Dose (mcg) Units (per injection) (mL)
Week 9 1000 mcg 90 units (0.90 mL)
Week 10 1100 mcg 99 units (0.99 mL)
Week 11 1200 mcg 108 units (1.08 mL)
Week 12 1300 mcg 117 units (1.17 mL)

Note: The 12-week extension reaches higher daily doses (1000–1300 mcg) that have been explored in performance and metabolic research settings[4]. These doses yield more significant physiological effects but also increase the potential for side effects. Further extension to 16 weeks (reaching 1700 mcg daily) may be considered in advanced protocols, though such aggressive regimens should be undertaken with appropriate monitoring.

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake vigorously to preserve protein structure)[5].
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

  • Peptide Vials (HGH 191AA, 10 IU / 3.33 mg each):
    • 8 weeks ≈ 10 vials
    • 12 weeks ≈ 19 vials
    • 16 weeks ≈ 32 vials
  • Insulin Syringes (U-100):
    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
    • 8 weeks (10 vials): 30 mL3 × 10 mL bottles
    • 12 weeks (19 vials): 57 mL6 × 10 mL bottles
    • 16 weeks (32 vials): 96 mL10 × 10 mL bottles
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.
    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100-count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100-count boxes
    • 16 weeks: 224 swabs → recommend 3 × 100-count boxes

Protocol Overview

Concise summary of the once-daily regimen.

  • Goal: Support increases in lean body mass, reductions in adipose tissue, and enhanced metabolic function[7][8].
  • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired for advanced protocols).
  • Dose Range: Conservative: 150–500 mcg daily[1]; Advanced: 1000–2000 mcg daily[4].
  • Reconstitution: 3.0 mL per 3.33 mg vial (~1.11 mg/mL) for accurate unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

  • Start: 200 mcg daily; increase by ~100 mcg each week as tolerated.
  • Conservative Target: 400–900 mcg daily by Weeks 4–8[1][8].
  • Advanced Target: 1000–1300 mcg daily by Weeks 9–12 (performance/metabolic research protocols)[4].
  • Frequency: Once per day (subcutaneous), preferably at bedtime[2].
  • Cycle Length: 8–12 weeks standard; optional extension to 16 weeks with appropriate monitoring.
  • Timing: Evening or bedtime administration preferred; rotate injection sites systematically[3].

Storage Instructions

Proper storage preserves peptide quality and bioactivity.

  • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); stable for several weeks when stored properly[5].
  • Allow vials to reach room temperature before opening to reduce condensation uptake.
  • Critical: Avoid freeze–thaw cycles of reconstituted peptide, as freezing can denature the protein[5].

Important Notes

  • Practical considerations for consistency and safety.
    • Use new sterile insulin syringes for each injection; dispose in a sharps container.
    • Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and prevent lipoatrophy[3].
    • Inject slowly; wait a few seconds before withdrawing the needle to minimize leakage.
    • Document daily dose, injection site, and any observed effects to maintain consistency and track tolerance.
    • HGH must be administered by injection; oral administration would be ineffective due to peptide degradation in the digestive system[6].

How This Works

HGH 191AA is recombinant human growth hormone (somatropin) that is structurally identical to endogenous GH secreted by the pituitary gland[1][5]. Clinical studies demonstrate that GH administration promotes increases in lean body mass, reductions in adipose tissue, and improvements in body composition through multiple mechanisms including enhanced lipolysis, increased protein synthesis, and stimulation of IGF-1 production[7][8]. Pivotal research by Rudman and colleagues showed that six months of HGH administration in older men significantly increased lean body mass and decreased adipose mass compared to placebo[7]. Long-term follow-up studies in adults with GH deficiency have demonstrated sustained improvements in muscle strength and body composition with maintenance dosing[8].

Subcutaneous administration once daily, particularly at bedtime, is designed to mimic physiological patterns of endogenous GH secretion[2][3]. Dosing protocols vary based on therapeutic goals: conservative replacement protocols typically employ 150–500 mcg daily[1], while advanced metabolic and performance research protocols may utilize 1000–2000 mcg daily[4]. Higher doses produce more pronounced physiological effects but also carry increased risk of side effects including fluid retention, joint discomfort, and potential metabolic disturbances[2].

Potential Benefits & Side Effects

Documented effects from clinical literature and medical practice.

Potential Benefits:

  • Fertility Preservation: Maintains intratesticular testosterone and spermatogenesis during TRT[3][4].
  • Testicular Size: Prevents or reverses testicular atrophy associated with exogenous testosterone use.
  • Testosterone Recovery: Restores endogenous testosterone production in hypogonadotropic hypogonadism or post‑cycle scenarios[5][6].
  • Hormonal Balance: Provides physiologic downstream hormone production (pregnenolone, DHEA) that exogenous testosterone alone does not provide.

Potential Side Effects:

  • Estradiol Elevation: HCG stimulates testicular aromatase, potentially increasing estradiol; may require monitoring and management.
  • Injection Site Reactions: Mild redness, swelling, or discomfort at injection sites (typically resolves quickly).
  • Acne/Oily Skin: Due to increased testosterone and estradiol production.
  • Testicular Discomfort: Occasional aching or sensitivity as dormant Leydig cells reactivate (usually temporary).
  • Gynecomastia Risk: Rare but possible if estradiol becomes significantly elevated without management.

Note: HCG is generally well‑tolerated at standard doses. Side effects are typically mild and manageable with dose adjustments or ancillary medications if needed.

Lifestyle Factors

Complementary strategies for optimizing outcomes.

  • Maintain adequate protein intake (1.6–2.2 g/kg body weight) to support anabolic processes stimulated by GH.
  • Combine resistance training and progressive overload to maximize lean mass gains and strength improvements.
  • Include cardiovascular activity to enhance metabolic adaptations and fat oxidation.
  • Prioritize sleep quality and duration (7–9 hours) to support endogenous recovery processes.
  • Manage stress and cortisol levels, as chronic stress can interfere with GH signaling and metabolic outcomes.
  • Ensure adequate hydration, particularly at higher doses where fluid retention may occur.

Injection Technique

Subcutaneous injection guidance from clinical best-practice resources[11][12].

  • Clean the vial stopper and injection site with alcohol; allow to air dry completely.
  • Pinch a skinfold at the injection site; insert the needle at 45–90° into subcutaneous tissue[11].
  • Do not aspirate for subcutaneous injections; inject slowly and steadily[11].
  • Rotate sites systematically (abdomen, thighs, upper arms) to prevent lipohypertrophy and lipoatrophy[3][13].
  • Common subcutaneous sites: abdomen (at least 2 inches from navel), outer thighs, upper arms (posterior surface)[12].
  • Wait a few seconds after injection before withdrawing needle to minimize solution leakage.

Recommended Source

Why Amino Labs?

  • Third-party tested: Each batch includes Certificate of Analysis (COA) verifying purity and composition.
  • Consistent quality: ISO-aligned manufacturing and handling standards ensure reliable product integrity.
  • Cold-chain integrity: Temperature-controlled shipping and storage throughout fulfillment process.
  • Research-grade purity: Suitable for educational and research applications requiring high-quality peptides.

Note: Product availability and specifications subject to change. Verify current product details on supplier website.

Shop at Amino Labs

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

References

Pfizer (Genotropin) Prescribing Information
— Adult GH deficiency dosing: recommended start 0.45–0.90 IU (0.15–0.30 mg) SC daily; maintenance dose seldom exceeds 4 IU (≈1.33 mg) daily
EMD Serono (Serostim) Prescribing Information
— HIV-associated wasting dose: 0.1 mg/kg SC daily (up to ~6 mg/day); administer injections subcutaneously, preferably at bedtime
Medsafe NZ Data Sheet (Omnitrope)
— Subcutaneous injection technique: site rotation to prevent lipoatrophy; recommends 0.15–0.30 mg per day to start in adults, titrating up to ~1.3 mg/day as needed
Hadzovic et al., Bosn. J. Basic Med. Sci. 2004
— GH usage and abuse review: moderate doses of GH (70–400 mcg in healthy adults) produce dose-dependent increases in lipolysis and fat oxidation
Saizen® (somatropin) FDA Label
— Lyophilized 191aa HGH is a sterile, white powder for SC or IM injection after reconstitution with bacteriostatic water; potency: 5 mg ≈ 15 IU and 8.8 mg ≈ 26.4 IU
Superior Peptide (Product Data)
— HGH 191AA is provided as a lyophilized powder intended for subcutaneous (or intramuscular) injection after reconstitution with bacteriostatic water
Rudman et al., N. Engl. J. Med. 1990
— Pivotal study in older men: six months of HGH (0.03 mg/kg 3× weekly) significantly increased lean body mass and decreased adipose mass compared to placebo
Götherström et al., J. Clin. Endocrinol. Metab. 2010
— 10-year adult GH deficiency follow-up: initial ~0.72 mg/day GH replacement (then reduced to ~0.37 mg/day long-term) led to sustained increases in muscle strength and improved body composition
Sathiavageeswaran et al., Clin. Endocrinol. 2007
— Trial in 60–77 y/o adults: low-dose GH (~0.16 mg/day for 12 months) was administered to evaluate cognitive effects, illustrating a conservative dosing regimen
Liu et al., Ann. Intern. Med. 2008
— Systematic review of GH in healthy athletes: GH administration increased lean body mass but did not significantly improve muscle strength or exercise performance
CDC Vaccine Administration Guidelines
— Subcutaneous injection technique: angle/site selection; no aspiration required for subcutaneous route
CDC Subcutaneous Injection Technique (PDF)
— Technique diagram and site guidance for subcutaneous injections
NCBI Bookshelf
— Best practices for injection: asepsis, preparation, and administration techniques